Development of New HIV Vaccine

Development of New HIV Vaccine

09-04-11

Innovayt helped SKAU vaccines to acquire funding from the Eurostars programme to develop an HIV vaccine. The project “HIVAC” commenced in May 2010 and will run for three years. The project will be using a novel approach of unmasking the immunosuppressive properties of the HIV envelope by introduction of rationally designed mutations. It is expected that the “HIVAC” project will result in the development of the first HIV vaccine that combines superior safety with an immune protection level that meets regulatory and market requirements.